Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: A systematic review

Cancer

Volumn 112, Issue 6, 2008, Pages 1197-1205

  Verma, Shailendra ^a,c   Younus, Jawaid ^b   Stys Norman, Denise ^c   Haynes, Adam E ^c   Blackstein, Martin ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Autologous bone marrow stem cell transplantation; Growth factor; High dose chemotherapy; Soft tissue sarcoma; Systematic review

Indexed keywords

DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA;

ADVANCED CANCER; ANEMIA; ASTHENIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; COCHRANE LIBRARY; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; EMBASE; FEBRILE NEUTROPENIA; HEART ARRHYTHMIA; HUMAN; INFECTION; INFORMATION RETRIEVAL; INOPERABLE CANCER; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MEDICAL INFORMATION; MEDLINE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SOFT TISSUE METASTASIS; SOFT TISSUE SARCOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH SUBSTANCES; HUMANS; SARCOMA; STEM CELL TRANSPLANTATION;

EID: 41149177493     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23302     Document Type: Review

References (35)

1. Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high grade soft-tissue sarcomas. J Clin Oncol. 1985;3:353-366.
2. Frost DB. Pulmonary metastasectomy for soft tissue sarcomas: is it justified? J Surg Oncol. 1995;59:110-115.
3. Van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675-682.
4. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4:103-112.
5. Antman KH, Montella D, Rosenbaum C, Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep. 1985;69:499-504.
6. Schutte J, Kellner R, Seeber S. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. Cancer Chemother Pharmacol. 1993;31(suppl 2):S194-S198.
7. Bramwell VHC, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. Cancer Chemother Pharmacol. 1993;31(suppl 2):S180-S184.
8. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11:1269-1275.
9. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977;39:1940-1948.
10. Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol. 1990;17(2 suppl 4):41-49.
11. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13:1600-1608.
12. Van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with 2 different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002; 38:2397-2406.
13. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group [comment]. J Clin Oncol. 1993;11:15-21.
14. Bui BN, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol. 1995;13:2629-2636.
15. Michelotti A, Romanini A, Giannessi P, Bengala C, Conte P. Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. Am J Clin Oncol. 1996;19:78-81.
16. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995;13:502-512.
17. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2676-2684.
18. Bui NB, Demaille MC, Chevreau C, et al. qMAID vs MAID + 25% with G-CSF in adults with advanced soft tissue sarcoma (STS). First results of randomized study of the FNCLCC sarcoma group [abstract]. Proc Am Soc Clin Oncol. 1998;17:517a. Abstract 1991.
19. Patel SR, Vadhan-Raj S, Burgess MA, et al. Dose-intensive chemotherapy with adriamycin, ifosfamide and growth factors in chemotherapy naive patients with soft tissue sarcomas [abstract]. Sarcoma 1997;1:198.
20. De Pas T, de Braud F, Orlando L, et al. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? [comment]. Ann Oncol. 1998;9:917-919.
21. Maurel J, Fra J, Lopez-Pousa A, et al. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 2004;100:1498-1506.
22. 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005;23:105-112.
23. Lin T-Y, Guang Z-Z, Su Y-S, Zhou Z-M, Liu D-G. High dose ifosfamide, doxorubicin, dacarbazine and G-CSF for patients with metastatic or locally advanced soft tissue sarcoma. Chin J Cancer Res. 1999;11:2005.
24. Schlemmer M, Wendtner CM, Falk M, et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology. 2006;71:32-39.
25. Siehl JM, Thiel E, Schmittel A, et al. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma. Cancer. 2005;104:611-617.
26. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998;16:1438-1443.
27. Palumbo R, Neumaier C, Cosso M, et al. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer. 1999;35:66-72.
28. Saeter G, Alvegard TA, Monge OR, et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. Eur J Cancer. 1997;33:1551-1558.
29. Buesa JM, Lopez-Pousa A, Martin J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol. 1998;9:871-876.
30. Almeida GF, Castro G, Snitcovsky I, et al. Phase II prospective study of dose-dense doxorubicin and ifosfamide in high-grade, locally advanced or metastatic soft tissue sarcoma (STS) patients [abstract]. J Clin Oncol. (Meeting Abstracts). 2007;25(18S). Abstract 20509.
31. Frustaci S, Buonadonna A, Galligioni E, et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol. 1997;15:1418-1426.
32. Frustaci S, Buonadonna A, Romanini A, et al. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. Tumori 1999;85:229-233.
33. De Pas T, Curigliano G, Masci G, et al. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. Ann Oncol. 2002;13:161-166.
34. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer. 1997;80:1221-1227.
35. Chevreau C, Bui BN, Chevallier B, et al. Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS). Am J Clin Oncol. 1999;22:267-272.